 Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and cancer-related conditions. Lineages clinical pipeline is based around three programs OpRegen Phase 12a for AMD, OPC1 Phase 2b3 for SCI, and VAC2 Phase 1 for NSCLC with a combined 40B potential market. 